Anti-angiogenic perfluorocarbon nanoparticles for diagnosis and treatment of atherosclerosis

Shelton D. Caruthers, Tillmann Cyrus, Patrick M. Winter, Samuel A. Wickline, Gregory M. Lanza

Research output: Contribution to journalArticlepeer-review

48 Scopus citations


Complementary developments in nanotechnology, genomics, proteomics, molecular biology and imaging offer the potential for early, accurate diagnosis. Molecularly-targeted diagnostic imaging agents will allow noninvasive phenotypic characterization of pathologies and, therefore, tailored treatment close to the onset. For atherosclerosis, this includes anti-angiogenic therapy with specificallytargeted drug delivery systems to arrest the development of plaques before they impinge upon the lumen. Additionally, monitoring the application and effects of this targeted therapy in a serial fashion will be important. This review covers the specific application of αvβ3-targeted anti-angiogenic perfluorocarbon nanoparticles in (1) the detection ofmolecular markers for atherosclerosis, (2) the immediate verification of drug delivery with image-based prediction of therapy outcomes, and (3) the serial, noninvasive observation of therapeutic efficacy.

Original languageEnglish
Pages (from-to)311-323
Number of pages13
JournalWiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
Issue number3
StatePublished - Dec 1 2009


Dive into the research topics of 'Anti-angiogenic perfluorocarbon nanoparticles for diagnosis and treatment of atherosclerosis'. Together they form a unique fingerprint.

Cite this